The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine. CHEManager asked executives and industry experts from a broad range of CDMOs to share their views on how their companies are dealing with this changing economic environment and the resulting opportunities and challenges.
The evolution of the CDMO sector is propelled by rising manufacturing standards, the advent of groundbreaking therapies, and a shift towards personalized medicine.
EuroAPI has entered into a Contract Manufacturing Organization (CMO) agreement with a global animal health company.
EuroAPI today announces that its Italian subsidiary, EuroAPI Italy S.R.L., is suspending the production of all APIs (active pharmaceutical ingredients) in Brindisi.
Active pharmaceutical ingredients manufacturer EuroAPI has started a collaboration with Basel, Switzerland-headquartered SpiroChem, a contract research organization (CRO) which specializes in early chemical process R&D (route scouting).
EuroAPI has appointed Ludwig de Mot as chief transformation officer and executive vice president (EVP).
EuroAPI has completed the acquisition of BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides.
EuroAPI's Board of Directors decided that Karl Rotthier would step down as CEO, effective October 30, 2023. They initiated the search for a new CEO and appointed Viviane Monges, the current Board Chair, as interim CEO until a permanent successor is found, while she continues her role as Board Chair.
Active pharmaceutical ingredients manufacturer EuroAPI has agreed to acquire BianoGMP, a contract development and manufacturing organization (CDMO) specializing in oligonucleotides. Biano is to become a EuroAPI company but retain its corporate brand.
Active Pharmaceutical Ingredient maker EuroAPI said it plans to invest €50 million in a new state-of-the-art production plant at its fully integrated Budapest site.
Leading active pharmaceutical ingredients manufacturer EuroAPI plans to invest €40 million at its site in Saint-Aubin-lès-Elbeuf, France, to launch a new production technology for vitamin B12. Full capacity is expected to be reached by 2027.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Executives and industry experts share their views on drivers as well as barriers for the use of flow chemistry in pharmaceutical manufacturing and the prospect for this technology in their industry sector.
Interview with Karl Rotthier, CEO of the Sanofi spin-off EuroAPI.
EuroAPI has announced it will spend €24 million to build a state-of-the-art biomass boiler at its Saint-Aubin-lès-Elbeuf (Seine-Maritime, France) site, planned to be installed by 2025.
Sanofi has announced it will list its Active Pharmaceutical ingredients company EuroAPI on the Euronext stock exchange in Paris on May 6. Each of the French drugmaker’s shareholders will receive one share in EuroAPI for 23 Sanofi shares in addition to a cash dividend of €3.33 per Sanofi share.
